Zoetis (ZTS)
82.96
+0.39 (0.47%)
NYSE · Last Trade: Nov 12th, 6:22 PM EST
News & Press Releases
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
Zoetis Inc. (NYSE: ZTS) today announced that the United States Department of Agriculture (USDA) has licensed Cytopoint Plus™ for the treatment of allergic dermatitis in dogs. Cytopoint Plus is the first and only USDA-licensed next-generation monoclonal antibody (mAb) that provides 75 days of allergic itch relief in a single injection — the longest treatment interval of any licensed mAb for canine allergic dermatitis.
By Zoetis Inc. · Via Business Wire · November 11, 2026
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT.
By Zoetis Inc. · Via Business Wire · November 10, 2026
What Zoetis (ZTS) Said on Its Q3 Earnings Callmarketbeat.com
Zoetis (NYSE:ZTS) reported lower third-quarter revenue as competition and weaker veterinary visits pressured its companion animal business, while livestock and diagnostics provided growth. The animal health company narrowed its full-year revenue outlook to the high end of its previous range and rais
Via MarketBeat · November 8, 2026
ZTS Q3 2026 deep dive: competitive pressures and margin headwinds weigh on outlook
Animal health company Zoetis (NYSE:ZTS) beat Wall Street’s revenue expectations in Q3 2026, but sales fell by 1.3% year on year to $2.39 billion. The company...
Via StockStory · November 6, 2026
Zoetis (NYSE:ZTS) Dividend Quality Backed by Strong Profitability and Health Ratingschartmill.com
Via Chartmill · November 2, 2026
Zoetis (NYSE:ZTS): A Quality Investing Case Study in Animal Healthchartmill.com
Via Chartmill · October 14, 2026
Zoetis (NYSE:ZTS): A Quality Dividend Stock for Income Investors With Room to Growchartmill.com
Via Chartmill · October 9, 2026
3 value stocks we think twice about
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...
Via StockStory · November 5, 2026
Zoetis: 3 Key Takeaways for Long-Term Investorsfool.com
Fast lifecycle approvals, such as Simparica Duo, are how Zoetis plans to extend its core franchises beyond today's pressured pet care market.
Via The Motley Fool · November 5, 2026
Zoetis (ZTS) Q3 2026 Earnings Call Transcriptfool.com
Competitive pressure eased in dermatology, but clinic visits softened
Via The Motley Fool · November 5, 2026
Zoetis (NYSE:ZTS) Looks Like a Decent Value Stockchartmill.com
Via Chartmill · September 25, 2026
Zoetis (NYSE:ZTS) posts better-than-expected sales in Q3 2026
Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q3 2026, but revenue fell by 1.3% year on year to $2.39 billi...
Via StockStory · November 5, 2026
Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance
Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026.
By Zoetis Inc. · Via Business Wire · November 5, 2026
Earnings to watch: Zoetis (ZTS) reports Q3 results tomorrow
Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu...
Via StockStory · November 3, 2026
1 healthcare stock with impressive fundamentals and 2 we ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...
Via StockStory · November 1, 2026
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Nowfool.com
The stocks listed here yield up to 5.8%.
Via The Motley Fool · October 27, 2026
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
Zoetis Inc. (NYSE: ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Convenia® RTU for Dogs (cefovecin injectable suspension) for the treatment of susceptible bacterial skin infections in dogs.
By Zoetis Inc. · Via Business Wire · October 20, 2026
3 Reasons ZTS is Risky and 1 Stock to Buy Instead
Zoetis has gotten torched over the last six months - since April 2026, its stock price has dropped 37.6% to $75.34 per share. This was partly due to its soft...
Via StockStory · October 15, 2026
Zoetis Appoints Iris Knobloch to its Board of Directors
Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. With decades of experience across global media and consumer businesses, Ms. Knobloch brings a distinct combination of international leadership, proven public company board experience across financial services, hospitality and media, and deep consumer and digital expertise to the Zoetis Board. She currently serves on the boards of Deezer S.A., Lazard, Inc. and Vail Resorts, Inc., and has built a track record of effective governance across complex, global organizations.
By Zoetis Inc. · Via Business Wire · October 13, 2026
Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...
Via StockStory · October 12, 2026
A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I'm Buying Right Nowfool.com
Whether you want a higher 3% dividend yield or a quickly growing dividend that yields 1.2%, these two stocks look like rare opportunities.
Via The Motley Fool · October 9, 2026
Zoetis Declares Fourth Quarter 2026 Dividend
The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026.
By Zoetis Inc. · Via Business Wire · October 8, 2026
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows that not all heartworm preventives perform equally against these resistant isolates. Macrocyclic lactone (ML) resistance means some heartworm isolates are less sensitive to the drug class used in today’s heartworm disease preventives. As ML resistance continues to challenge heartworm prevention, veterinarians need data that differentiate products at their labeled dosages to better inform their clinical decisions.
By Zoetis Inc. · Via Business Wire · October 6, 2026
Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief Operating Officer Jay Saccaro will review third quarter 2026 financial results and respond to questions from financial analysts.
By Zoetis Inc. · Via Business Wire · September 24, 2026
1 Mid-Cap Stock with Exciting Potential and 2 We Turn Down
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
Via StockStory · September 21, 2026